MediciNova's mid-stage study of MN-166 in progressive MS to continue as planned

• Based on a pre-planned interim analysis, the independent Data and Safety Monitoring Board recommends that MediciNova's (NASDAQ:MNOV +2.4%) Phase 2b study assessing lead product candidate MN-166 (ibudilast) for the treatment of progressive multiple sclerosis continue as planned.
• Final data from the study should be available in H2 2017. The primary endpoint is the mean rate of change in brain atrophy over 96 weeks as measured by a ratio called brain parenchymal fraction based on MRI images.